As at Feb 21, 2025, the UTHR stock has a PE ratio of 14.85. This is based on the current EPS of $24.31 and the stock price of $361.1 per share. An increase of 21% has been seen in the P/E ratio compared to the average of 12.3 of the last 4 quarters.
The mean historical PE ratio of UNITED THERAPEUTICS over the last ten years is 13.84. The current 14.85 PE ratio is 7% above the historical average. Over the past ten years, UTHR's PE ratio was at its highest in the Jun 2015 quarter at 47.14, with a price of $173.95 and an EPS of $3.69. The Jun 2016 quarter recorded the bottom point at 4.74, with a price of $105.92 and an EPS of $22.35.
Maximum annual increase: 254.1% in 2013
Maximum annual decrease: -76.49% in 2010
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2023 | 10.45 | -39.94% | $219.89 | $21.04 |
2022 | 17.4 | -14.62% | $278.09 | $15.98 |
2021 | 20.38 | 56.41% | $216.08 | $10.6 |
2020 | 13.03 | N/A | $151.79 | $11.65 |
2019 | N/A | N/A | $88.08 | -$2.39 |
2018 | 8.04 | -48.36% | $108.9 | $13.54 |
2017 | 15.57 | 76.93% | $147.95 | $9.5 |
2016 | 8.8 | -20.36% | $143.43 | $16.29 |
2015 | 11.05 | -39.75% | $156.61 | $14.17 |
2014 | 18.34 | -43.4% | $129.49 | $7.06 |
2013 | 32.4 | 254.1% | $113.08 | $3.49 |
2012 | 9.15 | -26.21% | $53.42 | $5.84 |
2011 | 12.4 | -62.93% | $47.25 | $3.81 |
2010 | 33.45 | -76.49% | $63.22 | $1.89 |
2009 | 142.3 | N/A | $52.65 | $0.37 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Sep 2024 | 14.74 | 6.81% | $358.35 | $24.31 |
Jun 2024 | 13.8 | 34.37% | $318.55 | $23.09 |
Mar 2024 | 10.27 | -1.72% | $229.72 | $22.36 |
Dec 2023 | 10.45 | -10.84% | $219.89 | $21.04 |
Sep 2023 | 11.72 | 0% | $225.87 | $19.28 |
Jun 2023 | 11.72 | -17% | $220.75 | $18.83 |
Mar 2023 | 14.12 | -18.85% | $223.96 | $15.86 |
Dec 2022 | 17.4 | 29.75% | $278.09 | $15.98 |
Sep 2022 | 13.41 | -20.51% | $209.38 | $15.61 |
Jun 2022 | 16.87 | 43.45% | $235.64 | $13.97 |
Mar 2022 | 11.76 | -42.3% | $179.41 | $15.26 |
Dec 2021 | 20.38 | 13.92% | $216.08 | $10.6 |
Sep 2021 | 17.89 | 5.3% | $184.58 | $10.32 |
Jun 2021 | 16.99 | -7.16% | $179.41 | $10.56 |
Mar 2021 | 18.3 | 40.45% | $167.27 | $9.14 |
Currently, UTHR's PE ratio is greater than its 3, 5 and 10-year historical averages.
UTHR's PE ratio is lower than its peer stocks LLY and PFE.
Stock name | PE ratio | Market cap |
---|---|---|
UTHR UNITED THERAPEUTICS Corp | 14.85 | $16.12B |
CAH Cardinal Health Inc | 23.57 | $30.69B |
PFE Pfizer Inc | 34.61 | $149.04B |
LLY ELI LILLY & Co | 74.29 | $828.4B |
GILD Gilead Sciences Inc | 1,099.5 | $137.03B |
TEVA Teva Pharmaceutical Industries Ltd | N/A | $18.98B |
BAX Baxter International Inc | N/A | $17.3B |
CYTK Cytokinetics Inc | N/A | $5.93B |
As of Feb 21, 2025, UTHR stock has a price to earnings ratio of 14.85.
The 3-year average PE ratio for UTHR stock is 13.3.
The 5-year average PE ratio for UTHR stock is 13.82.
Over the last ten years, the quarterly PE ratio reached a historic high of 47.14 in the Jun 2015 quarter.
UTHR's current price to earnings ratio is 7% above its 10-year historical average.
The PE ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Feb 21, 2025), UNITED THERAPEUTICS's stock price is $361.1. The earnings per share for the trailing twelve months (TTM) ending Sep 2024 is $24.31. Therefore, UNITED THERAPEUTICS's P/E ratio for today is 14.85. PE RATIO(14.85) = STOCK PRICE($361.1) / TTM EPS($24.31)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.